CC-90002（Cat No.:I043209）is an investigational drug being developed by the pharmaceutical company Celgene (now part of Bristol-Myers Squibb) for the treatment of various types of cancer. It is a selective oral inhibitor of the protein menin, which plays a role in regulating gene expression and is involved in certain cancers, including leukemia and solid tumors. By inhibiting menin, CC-90002 aims to block the oncogenic pathways that drive tumor growth. It is being evaluated in clinical trials for its effectiveness in treating hematologic malignancies, particularly acute leukemias with specific genetic mutations.
